作者: Tadayuki Kou , Masashi Kanai , Mayumi Kamada , Masahiko Nakatsui , Shigemi Matsumoto
DOI: 10.1007/978-1-4939-8639-2_14
关键词:
摘要: Recent innovations in next-generation sequencing (NGS) technologies have enabled comprehensive genomic profiling of human cancers the clinical setting. The ability to profile has launched a worldwide trend known as precision medicine, and fusion pharmacogenomics is paving way for medicine cancer. coupled with information about chemical therapies available patients specific genotypes. As result, chemogenomic space play not only standard genome but also mutational space. In this chapter, we introduce using an NGS-based multiplex gene assay (OncoPrime™) at Kyoto University Hospital.